Ann: Next Science enters into US$5m unsecured loan facility, page-20

Tomorrow is the presentation. It will be an interesting presentation, no doubt.
It will either validate what management has reiterated last quarterly (that we will be EBITDA +ve and Cashflow +ve by this H2 2025) or it will completely be off the mark and we get further delays to break-even.

Given that in the previous Quarterly they reiterated guidance, this quarterly should at least show some improvements in CF. If the results do not show a slowing and closing of the gap to break-even, then I think the new management would have lost some credibility by lying through their teeth. On the other hand, if they do show improvements as per guidelines, then I think management would have done a great job.

Here's hoping that the $5m loan that we recently got will give us enough working capital to get us to break-even in Q3 and Q4.

Let's see how we go tomorrow.